Compare Cisco Systems Inc (CSCO) vs TG Therapeutics Inc (TGTX) Price & Performance

Cisco Systems (CSCO) trades at $122.57, up 0.94% today, near its recent highs driven by strong AI cybersecurity momentum. The stock shows bullish technical signals with moving averages supporting the uptrend, while RSI levels indicate potential overbought conditions. Fundamentally, CSCO reported revenue of $56.65B in 2025 with a net income margin of 19.69%, and has beaten EPS estimates for three consecutive quarters. Recent news highlights partnerships and product launches in AI security, fueling investor optimism.

CSCO's outlook is positive with a consensus price target of $133.25, implying ~9% upside, supported by 52% analyst buy ratings. Key opportunities include growth in AI-driven networking and security demand, but risks involve high valuation multiples (P/E 40.14) and competitive pressures in the tech sector. Investors should weigh strong cash flow generation against execution risks in a dynamic market.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.